With aducanumab approved and another similar drug on the way if anything I am worried it will stick around. It is literally the only endpoint that demonstrated any significant difference in the trial.
I just think we haven't a clue. When I was still doing my PhD scRNASeq was the new hotness. I think in bio world we end up like getting a new hammer and everything is a nail. I think with a lot of disease research where we've made almost no progress (Alzheimers is a good one) we need to be thinking wildly outside of the box and starting from ground up. I am not smart enough to do that but we need people who are.